Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective

Egle Ramelyte(University of Zurich), Reinhard Dummer(University Hospital of Zurich)

Cancer Cell

January 21, 2021

10.1016/j.ccell.2020.12.022

Cited by 108

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

|New England Journal of Medicine|2011|7.7k

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

|New England Journal of Medicine|2017|1.5k

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

|Nature|2010|1.4k

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

|Blood|2007|1.4k

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

|New England Journal of Medicine|2017|1.4k